Health Canada has approved Teva Canada Limited’s application for its tobramycin inhalation solution, a generic version of Novartis’s TOBI inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients in Canada. The Teva tobramycin inhalation solution is now available in Canadian pharmacies, the company said.
Teva Canada Limited General Manager Doug Sommerville commented, “Cystic fibrosis is a devastating genetic disorder where nearly half of the 4,000 affected Canadians will become infected with harmful bacterial in their lungs caused by Pseudomonas aeruginosa. As the sole generic supplier of tobramycin inhalation solution we endeavor to play an active role in supplying patients with a lower cost option to help facilitate the medical treatment of this infection.”
Read the Teva Canada press release.
